Autopsy report · NCT03516695

RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry

“due to Sponsor's ongoing and upcoming projects and overall research priorities”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 10 months before it stopped.
• 95 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Boston Scientific Corporation

Sponsor type

Industry

Conditions

Liver Cancer

Interventions

TheraSphere®

Participants

95

Sites

8

Countries

Canada, United States

Trials that died the same way

• Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.
  “For interests of sponsor.” (70% match in meaning)
• OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer
  “Due to sponsor request” (69% match in meaning)
• Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS
  “Due to sponsor decision” (69% match in meaning)
• BST-DERMON Versus Standard of Care in the Treatment of Diabetic Foot Ulcers
  “Due to Sponsor's financial reasons” (69% match in meaning)
• Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND1 Mutations
  “Due to the sponsor circumstances and external reasons” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.